Contributors: T Boyles, F Conradie, V Cox, A Grimsrud, J Hughes, J Nel, A Reuter, L Wilkinson
To support TB patients during the COVID-19 pandemic, it is critical both to patients and the healthcare system to minimise visits to health facilities. This document outlines key adaptations to the TB care service delivery that should be considered to reduce health facility visits during the COVID-19 pandemic. This guidance prioritises how to provide uninterrupted TB treatment in resource constrained health systems with a high burden of TB. In addition to outlining recommended service delivery approaches for drug-susceptible (DS-TB) and drug-resistant TB (DR-TB) patients, guidance on additional areas (including patient support, contact tracing, provision of the influenza vaccine, differentiating TB from COVID-19 and telephonic monitoring) is provided.
National Department of Health
UNAIDS | 2020
Department of Health
Recommendations from the Southern African HIV Clinicians Society (SAHCS) for COVID-19
National Institute for Communicable Diseases (NICD)
Francesca Conradie, et al
Nix-TB Trial. Published in The New England Journal of Medicine
Guy Thwaites and Payam Nahid
Triumph and Tragedy of 21st Century
Tuberculosis Drug Development.
Published in The new England Journal of Medicine.
Published in The New England Journal of Medicine
Please see the letter and instructions about how to access the guidelines via the EMGuidance mobile phone application.
This edition of UNAIDS data shows the results of some of the successes, but also the challenges that remain. It contains the very latest data on the world’s response to HIV, consolidating a small part of the huge volume of data collected, analysed and refined by UNAIDS over the years. The full data set of information for 1990 to 2018 is available on aidsinfo.unaids.org.
Interim guidance while abacavir/lamivudine, abacavir singles, lamivudine singles and abacavir/zidovudine (2nd Line) are out of stock updated 18.07.2019
Please click on the link to download the template for patients on treatment and distribution of medicines.
This document needs to be submitted to NDoH on a monthly basis by provinces in terms of usage of items obtained using bulk Section 21. Each province is required to collate different facility reports and submit their consolidated report every month.
Forum on the risks of preconception dolutegravir exposure
Interim guidance while abacavir/lamivudine, abacavir singles and lamivudine singles (2nd Line) are out of stock
Interim guidance while abacavir/lamivudine, abacavir singles and lamivudine singles are out of stock
Reproductive health rights of women in South Africa under threat, as supply shortages leave health facilities across the country without supplies of contraceptives.
Statement by the African Community Advisory Board (AfroCAB) on Dolutegravir and neural tube defects in women living with HIV of child bearing age.
Monthly update shared with all members involved in projects aimed at optimising ART.
What you need to know
For adults and paediatrics
DTG in pregnancy
North-West Province: A health system on its knees
The Southern African Journal of HIV Medicine accepted onto PubMed Central®
Statement on 5-FC for cryptococcal meningitis.
What it is and how to integrate it into HIV Testing Services
In a large South African cohort study, a team of researchers from the University of the Witwatersrand (Johannesburg, Gauteng, South Africa), the Ndlovu Research Consortium (Groblersdal, Limpopo, SA), the National Health Laboratory Service (SA), the University of California San Diego (USA), and the University Medical Center Utrecht (The Netherlands) found that low level viremia in treated HIV-patients is an important risk factor for treatment failure.
Please find attached the application form that is required to be completed for access to Third Line Antiretroviral Therapy. Please complete the form using the following steps:
• Download: Please download the PDF document.
• Open: Open the PDF document using Adobe Reader. Ensure you have the latest version of the form may not work properly.
• Fill: This is an editable PDF, and the minimum required fields will be highlighted. Please click on each field and enter the required patient information.
Please do not print out the document to complete by hand.
• Save: Once you have completed the document please save it to your computer by clicking the icon on the top left of the screen. Save it using the patient name and surname as a unique identifier.
• Submit: Close Adobe and attach the completed and renamed application form to an email and submit it to the following email address: TLART@health.gov.za
This TLART application form has been formatted to allow the data to be electronically extracted.
The fields must be inputted electronically. There is no need for electronic signatures and the form to be 'closed' - this actually blocks the electronic extraction. You will note some fields are outlined in red. This however does not block the user from sending if they are not completed, but prompts you to fill in the minimum requirements.
A flipchart to highlight key points
From 1 October 2016, labs across South Africa have “switched on” reflex CrAg screening. We expect to screen 250,000 people with CD4<100 per year across SA. This should improve early case detection. This is a significant milestone after many years of advocacy. Here’s a link to an online article targeted at the general public: http://theconversation.com/a-new-meningitis-screening-test-could-help-cut-south-africas-hiv-aids-deathtoll-69452
How close is South Africa to reaching the UNAIDS HIV treatment targets?
World Health Organization
WHO recommends assistance for people with HIV to notify their partners
WHO recommends HIV self-testing
National Department of Health, National Health Laboratory Service, National Institute for Communicable Diseases, Right to Care
Groundbreaking data system set to accelerate HIV/Aids elimination in South Africa
Health Systems Trust
This first volume of the 90-90-90 Compendium is targeted at a wide range of readers in South Africa, including community members and/ or politicians with no medical background. It is designed to assist all health sector role-players in understanding the context of the 90-90-90 strategy, as developed by the Joint United Nations Programme on HIV/AIDS (UNAIDS), and then the process for achieving the strategy’s targets.
Third Annual Report - South Africa
Prepared by the National Department of Health
Implementation of the universal Test and Treat strategy for HIV positive patients and differentiated care for stable patients
The session is hosted by the Centre for Infectious Disease Epidemiology and Research (CIDER) in the School of Public Health & Family Medicine at the University of Cape Town; Anova Health Institute; the International Epidemiologic Databases to Evaluate AIDS network - Southern Africa (IeDEA-SA); ICAP at Columbia University; and the Southern African HIV Clinicians Society.
This is the latest version of the National Department of Health's "Standard treatment guidelines and essential medicines list for SA" - Hospital level adult edition.
This workshop on 13-15 July 2016 will be held at UCT and is ideal for anyone with a research, laboratory or clinical interest in fungal pathogens in HIV infected individuals.
The 2016 "National Policy on HIV Pre-exposure Prophylaxis (PrEP) and Test and Treat (T&T)" has been released by the SA National Department of Health
The 2016 "Guidelines for Expanding Combination Prevention and Treatment Options for Sex Workers: Oral Pre-Exposure Prophylaxis (PrEP) and Test and Treat (T&T)" have been released by the SA National Department of Health.
This is a shareable PDF with information about a new Global Community for Sex, HIV And Reproductive Empowerment/Global SHARE. This is a community of providers, civil society members and PLHIV who are interested in addressing the reproductive needs and rights of PLHIV.
The Southern African HIV Clinicians Society supports evidence-based law- and policy-making. We believe that South Africa will not reach our own, as well as international, HIV reduction and treatment targets or related public health goals if it does not decriminalise adult sex work.
The aim of the this PrEP guideline is to explain what PrEP is, outline current indications for its use, outline steps for appropriate user selection and provide guidance to monitor and maintain PrEP users.
This document is a corrigendum to our "Guideline on the management of occupational and non-occupational exposure to the human immunodeficiency virus and recommendations for post-exposure prophylaxis: 2015 Update".
This guideline is an update of the post-exposure prophylaxis (PEP) guideline published by the Southern African HIV Clinicians Society in 2008.
This document contains all the information and the nomination form pertaining to the Society's 2016 board elections.
This document, and the associated circular (FDC ARV Circular, dated 25.05.2015) provides guidance on how to prescribe FDCs. This reduces the need to use single-agent lamivudine tablets.